Alzheimers Disease Clinical Trial
Official title:
A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808
[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.
Siemens Molecular Imaging (SMI) is seeking to determine if [F-18]T808 might be useful as a non-invasive assessment tool in the clinical evaluation of subjects with conditions associated with tau protein aggregates, such as Alzheimer's disease. The information collected under this exploratory study will not be used for diagnostic purposes, assessments of the participant's response to therapy or for clinical management of the participants. However, this exploratory study will provide baseline information on the safety, biodistribution, and dosimetry of [F-18]T808. These data will aid in the design of future studies of [F-18]T808 in patients with Alzheimer's disease. Overall, this study will provide initial data that inform the development of [F-18]T808 as the first PET imaging agent for human tau protein related pathology. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
| Terminated |
NCT02565511 -
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01993836 -
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
|
Phase 4 | |
| Terminated |
NCT05097131 -
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
|
||
| Completed |
NCT00448799 -
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04639050 -
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Terminated |
NCT06424236 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05891496 -
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
|
Phase 3 | |
| Terminated |
NCT01733355 -
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
|
Phase 0 | |
| Completed |
NCT00911690 -
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|
N/A | |
| Recruiting |
NCT01479855 -
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
|
N/A | |
| Completed |
NCT01469351 -
Identifying Potential Effects of Liraglutide on Degenerative Changes
|
N/A | |
| Completed |
NCT00439010 -
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05269394 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01760005 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
|
Phase 2/Phase 3 | |
| Completed |
NCT04623242 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
|
Phase 2/Phase 3 | |
| Suspended |
NCT05552157 -
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
| Completed |
NCT04023994 -
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT03131453 -
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01946243 -
The Feasibility of Florbetapir Quantitation
|
Phase 4 |